0000950170-23-052171.txt : 20231005 0000950170-23-052171.hdr.sgml : 20231005 20231005151354 ACCESSION NUMBER: 0000950170-23-052171 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231003 FILED AS OF DATE: 20231005 DATE AS OF CHANGE: 20231005 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SMITH IAN F CENTRAL INDEX KEY: 0001197032 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38360 FILM NUMBER: 231311126 MAIL ADDRESS: STREET 1: C/O ACORDA THERAPEUTICS, INC. STREET 2: 420 SAW MILL RIVER ROAD CITY: ARDSLEY STATE: NY ZIP: 10502 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Solid Biosciences Inc. CENTRAL INDEX KEY: 0001707502 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 900943402 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 500 RUTHERFORD AVENUE STREET 2: 3RD FLOOR CITY: CHARLESTOWN STATE: MA ZIP: 02129 BUSINESS PHONE: 617-337-4680 MAIL ADDRESS: STREET 1: 500 RUTHERFORD AVENUE STREET 2: 3RD FLOOR CITY: CHARLESTOWN STATE: MA ZIP: 02129 FORMER COMPANY: FORMER CONFORMED NAME: Solid Biosciences, LLC DATE OF NAME CHANGE: 20170524 4 1 ownership.xml 4 X0508 4 2023-10-03 0001707502 Solid Biosciences Inc. SLDB 0001197032 SMITH IAN F C/O SOLID BIOSCIENCES INC. 500 RUTHERFORD AVENUE, THIRD FLOOR CHARLESTOWN MA 02129 true false false false false Common Stock 2023-10-03 4 M false 15569 A 84378 D Restricted Stock Units 2023-10-03 4 M false 15569 0 D Common Stock 15569 15570 D Restricted units convert to common on a one-for-one basis. The restricted stock units were granted on January 3, 2023 (the "Grant Date") and vest in equal quarterly installments beginning three months from Grant Date, with the final installment vesting the date that is 12 months from the Grant Date; provided that in the event of early termination of the First Amendment to the Executive Chair Agreement between the Issuer and the reporting person (the "Smith Agreement") prior to the expiration of the Term (as defined in the Smith Agreement) and/or a change in control of the Issuer, the restricted stock units shall accelerate in full. /s/ David Tyronne Howton as attorney-in-fact for Ian F. Smith 2023-10-05